Testing where an imaging drug goes in the body in people with glioblastoma or pancreatic cancer
Original title: Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people to see where the drug goes and how safe it is.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study looks at how an imaging drug spreads through the body and how much radiation organs get.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a type of brain tumor, or with pancreatic ductal adenocarcinoma. It tests an imaging drug called 203Pb-RMX-VH-PIB, given as one shot into a vein, followed by several SPECT/CT scans.
Where it stands. The trial has not reported results. It is measuring where the drug spreads in the body and how much radiation each organ receives. Blood, urine, vital signs, and heart tracings are watched for safety. People are followed for side effects for up to 30 days. The answers are not in yet.
What this means, and what it doesn't
What it could mean: This is an imaging drug, not a treatment. It is being studied to see where it goes in the body and what radiation dose organs get. Someone who fits this study could ask their care team about it.
What it doesn't mean: This does not mean the drug has been shown to work. A trial is a test, not a proven treatment. Being in one is not a guarantee of any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.